These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 19954970)
1. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Venkatesan AM; Dehnhardt CM; Chen Z; Santos ED; Dos Santos O; Bursavich M; Gilbert AM; Ellingboe JW; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham R; Mansour TS Bioorg Med Chem Lett; 2010 Jan; 20(2):653-6. PubMed ID: 19954970 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors. Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367 [TBL] [Abstract][Full Text] [Related]
3. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode. Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896 [TBL] [Abstract][Full Text] [Related]
4. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669 [TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K. Verheijen JC; Yu K; Toral-Barza L; Hollander I; Zask A Bioorg Med Chem Lett; 2010 Jan; 20(1):375-9. PubMed ID: 19897362 [TBL] [Abstract][Full Text] [Related]
6. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Kaplan J; Verheijen JC; Brooijmans N; Toral-Barza L; Hollander I; Yu K; Zask A Bioorg Med Chem Lett; 2010 Jan; 20(2):640-3. PubMed ID: 19963384 [TBL] [Abstract][Full Text] [Related]
8. Novel benzofuran-3-one indole inhibitors of PI3 kinase-alpha and the mammalian target of rapamycin: hit to lead studies. Bursavich MG; Brooijmans N; Feldberg L; Hollander I; Kim S; Lombardi S; Park K; Mallon R; Gilbert AM Bioorg Med Chem Lett; 2010 Apr; 20(8):2586-90. PubMed ID: 20303263 [TBL] [Abstract][Full Text] [Related]
9. 4-Substituted-7-azaindoles bearing a ureidobenzofuranone moiety as potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Tsou HR; MacEwan G; Birnberg G; Zhang N; Brooijmans N; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K Bioorg Med Chem Lett; 2010 Apr; 20(7):2259-63. PubMed ID: 20188551 [TBL] [Abstract][Full Text] [Related]
10. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization. Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477 [TBL] [Abstract][Full Text] [Related]
11. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402. Dehnhardt CM; Venkatesan AM; Delos Santos E; Chen Z; Santos O; Ayral-Kaloustian S; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Chaudhary I; Yu K; Gibbons J; Abraham R; Mansour TS J Med Chem; 2010 Jan; 53(2):798-810. PubMed ID: 19968288 [TBL] [Abstract][Full Text] [Related]
12. Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Gilbert AM; Nowak P; Brooijmans N; Bursavich MG; Dehnhardt C; Santos ED; Feldberg LR; Hollander I; Kim S; Lombardi S; Park K; Venkatesan AM; Mallon R Bioorg Med Chem Lett; 2010 Jan; 20(2):636-9. PubMed ID: 19969455 [TBL] [Abstract][Full Text] [Related]
17. ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines. Zask A; Verheijen JC; Curran K; Kaplan J; Richard DJ; Nowak P; Malwitz DJ; Brooijmans N; Bard J; Svenson K; Lucas J; Toral-Barza L; Zhang WG; Hollander I; Gibbons JJ; Abraham RT; Ayral-Kaloustian S; Mansour TS; Yu K J Med Chem; 2009 Aug; 52(16):5013-6. PubMed ID: 19645448 [TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552 [TBL] [Abstract][Full Text] [Related]
19. Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR. Menear KA; Gomez S; Malagu K; Bailey C; Blackburn K; Cockcroft XL; Ewen S; Fundo A; Le Gall A; Hermann G; Sebastian L; Sunose M; Presnot T; Torode E; Hickson I; Martin NM; Smith GC; Pike KG Bioorg Med Chem Lett; 2009 Oct; 19(20):5898-901. PubMed ID: 19733066 [TBL] [Abstract][Full Text] [Related]
20. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]